HR-5880-119
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Harriet Hageman (R-WY)
What it does
This bill would amend the Controlled Substances Act to require that tableting machines, encapsulating machines, and their critical parts (upper punches, lower punches, and dies) bear permanently affixed serial numbers. Regulated persons — including manufacturers, distributors, importers, exporters, and brokers — would be required to record and report those serial numbers to the Attorney General when conducting transactions involving these machines. The bill would also make it a federal crime to remove, alter, or obliterate a required serial number, or to knowingly handle such equipment with an altered or missing serial number. The Attorney General would have 180 days to issue implementing regulations.
Who benefits
Law enforcement agencies that would gain a traceability tool to track pill-pressing equipment used in illicit fentanyl and counterfeit pill manufacturing. Communities disproportionately affected by synthetic opioid overdoses. Legitimate pharmaceutical manufacturers who already comply with similar tracking standards and may benefit from a more level regulatory playing field. Drug enforcement investigators who could use serial number records to build cases against illicit drug networks. Families and individuals affected by counterfeit pill-related deaths.
Who is hurt
Legitimate small-scale manufacturers and distributors of tableting and encapsulating equipment who would bear compliance costs — including retrofitting serial numbers onto machines manufactured before the bill's enactment. Research institutions, compounding pharmacies, and nutraceutical or supplement manufacturers that use these machines for lawful purposes and would face new recordkeeping and reporting burdens. Importers and exporters of this equipment who would need to update transaction documentation. Businesses that deal in used or refurbished pill-press equipment, who may face uncertainty about retroactive serial number requirements.
Supporters argue
Supporters argue that illicitly manufactured fentanyl — often pressed into counterfeit pills using untracked tableting machines — is the leading driver of U.S. overdose deaths, which exceeded 70,000 fentanyl-related fatalities in 2023 according to CDC data. They contend that serial number requirements, modeled on analogous traceability systems for firearms, would give law enforcement a concrete investigative tool to trace pill-press equipment from point of manufacture to point of seizure, disrupting supply chains for counterfeit drugs. They further argue the bill imposes minimal burden on the large, established pharmaceutical industry while closing a meaningful gap in the existing regulatory framework.
Opponents argue
Opponents argue that criminal drug manufacturers who already operate outside the law are unlikely to comply with serial number requirements, meaning the burden would fall almost entirely on legitimate businesses while doing little to deter illicit actors who can source equipment through black markets or manufacture their own components. They contend that retrofitting serial numbers onto existing machines — particularly the critical parts like punches and dies, which are small, numerous, and frequently replaced — would impose significant and potentially unworkable compliance costs on small manufacturers, compounding pharmacies, and research labs. They also argue the bill delegates broad regulatory discretion to the Attorney General with limited congressional guidance on standards.